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Abstract
Background: Contact lens-related infections are often associated with inadequate contact lens hygiene, and
therefore, contact lens care products should be able to sufficiently minimise the amount of pathogens that are
responsible for these infections. In 2001, the EN ISO 14729 was introduced to ensure adequate disinfection efficacy
of contact lens care solutions, but this norm has recently been criticised.
Methods: In this study, six frequently used contact lens care solutions were retested according to the Stand Alone
Test of the EN ISO 14729 (2001). The Stand Alone Test is a quantitative suspension test. In addition, the products
were tested in a modified setting adding an organic load. The load was a mixture of human blood serum,
lysozyme, and mucine, which resembles tear fluid.
Results: The criteria of the Stand Alone Test recommended in EN ISO 14729 were only met by Aosept Plus. This 3%
hydrogen-peroxide-based contact lens care solution attained a reduction factor of > 5 log units for bacteria and
> 4 for fungi in all cases. Two further contact lens care solutions, Blue Vision and Optifree Replenish, met the criteria
of a reduction factor of > 3 log units for bacteria and > 1 log unit for fungi, but only in the presence of artificial
tear fluid. The three remaining products did not exhibit adequate disinfecting efficacy, at least against one of the
tested microorganisms.
Conclusions: Through the observation that the artificial tear fluid used in this study influences the disinfecting
efficacy of contact lens care solutions, especially that of multi-purpose solutions, in a different way than does
albumin, mucine, or even the organic load suggested in EN ISO 14729, it becomes obvious that the test conditions
in the EN ISO 14729 should be revised in order to create more realistic conditions, e.g., by using a more realistic
artificial tear fluid. Furthermore, we suggest adapting the EN ISO 14729 to the European test hierarchy for chemical
disinfectants and antiseptics, which consists of three test phases and also requests meeting stricter criteria in order
to pass the test. Unless the test conditions guarantee a sufficient reduction of potential pathogens, the risk of
contact lens-related microbial keratitis and other infections will remain for the users.
Keywords: Contact lens care solutions, Microbicidal activity, EN ISO 14729
Background
In developed countries, contact lens (CL) wear, especially
hydrogel CL wear, is the most common risk factor for
microbial keratitis [1-10] and has steadily increased over
the past decades [11]. In the aetiology of CL-associated
microbial keratitis, Pseudomonas spp. [11,12] dominate,
followed by other bacteria species, fungi, and Acanth-
amoeba [5,11-29]. In many cases, infections are initiated
by the CL wearers themselves. One of the major risk
factors is the inadequate hygiene in handling CLs and
their accessories [1,30-32]. Numerous studies have con-
cluded that up to 90% of CL wearers are non-compliant
with at least some of their CL care regimen [33-36]. This
non-compliance is thought to result, for example, from
the lack of understanding proper CL care procedures by
the CL wearers [33], or from misinformation and misin-
terpretation of practitioners’ instructions [36].
In the light of these findings, it is essential that CL
care products, especially CL care solutions, should be
designed to sufficiently decrease the amount of potential
pathogens in order to minimise the risk of CL-related
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infections. CL care products should ideally have a cer-
tain level of ‘excess efficacy’, or safety margin [36,37].
Unfortunately, different CL care solutions do not even
provide a minimum of safety for the wearer and had to
be taken off the market as they were associated with CL-
related microbial keratitis [11,38-44]. In addition to
these issues, numerous studies have shown that CLs, CL
cases and CL care solutions can be loaded with up to
107 colony forming units (CFU) of bacterial, amoebic
and even viral pathogens [18,25,45,46].
To improve the situation, the EN ISO 14729 [47] was
introduced in 2001 to ensure the disinfection efficacy of
CL care solutions. CL care solutions are required to be
tested according to this harmonised norm, as they are
classified as medical devices Class IIb according to 93/
42/EEC [48] rule 15: All devices intended specifically to
be used for disinfection, cleaning, rinsing or, when ap-
propriate, hydrating contact lenses are in Class IIb.
However, the EN ISO 14729 was designed with the as-
sumption that the CL wearers perform an adequate rub-
and-rinse regimen [49]. Nevertheless, especially for CL
wearers who do not comply with their CL care regimen,
it is crucial that CL care solutions not only meet the EN
ISO Stand Alone primary criteria, but also exceed them
under more realistic conditions [50-52]. Therefore, vari-
ous studies have been conducted on the basis of EN ISO
14729 with an added organic load, with the result that
most products failed, especially the multi-purpose solu-
tions [45,53].
In this study, six CL care solutions, mainly based on
hydrogen peroxide, were retested according to the EN
ISO 14729 [47]. There was special focus on creating a
realistic setting by adding an organic load (artificial tear
fluid) to the test conditions.
Methods
Contact lens care solutions
The CL care solutions listed in Table 1 were used
according to the respective manufacturer’s instructions.
The CL care solutions were assessed before their stated
expiration dates and were taken from their original
packaging.
Microorganisms
The test organisms Pseudomonas aeruginosa (ATCC
9027), Staphylococcus aureus (ATCC 6538), Serratia
marcescens (ATCC 13880), Candida albicans (ATCC
10231) and Fusarium solani (ATCC 36031) were grown
according to EN ISO 14729 (2001) [47].
Artificial tear fluid
The artificial tear fluid was prepared by adding 0.5% of
the tear-specific protein lysozyme (chicken egg lysozyme,
Sigma Aldrich, Steinheim, Germany) and 0.1% of mucine
(from porcine stomach, Sigma Adrich, Steinheim, Ger-
many) to human blood serum. Human blood serum was
used because of its similarity to natural tear fluid in
terms of pH, osmolarity, ionic strength, and protein
composition [54-57]. The serum was obtained from
healthy blood donors at the Department of Transfusion
Medicine of the University of Greifswald (Germany).
Donors gave informed consent to provide an additional
blood sample of 8 ml whole blood for research purposes.
Fresh serum samples were collected daily in 10 ml tubes
and used immediately. The amount of artificial tear fluid
required for the quantitative suspension tests to simulate
realistic conditions was determined by using a dry-
weight method: hydrogel CLs were dried for 4 h using a
desiccator and were weighed afterwards. The dried CLs
were immersed in artificial tear fluid for 8 h, then dried
and weighed again. The mean value of the calculated dif-
ferences was approximately 0.1 g for two CLs. Therefore,
0.1 ml artificial fluid was determined for use in further
quantitative suspension tests.
Quantitative suspension test method
The quantitative suspension tests were performed in ac-
cordance with EN ISO 14729 (2001) [47]. 0.1 ml of
broth culture (for bacteria ca. 109 CFU/ml, for yeast ca.
108 CFU/ml) was transferred into 10 ml CL care
Table 1 Contact lens care solutions
trade name manufacturer/
distributor
active ingredient MMRDT overnight inactivation solution
AOSEPT PLUS Ciba Vision 3.0% H2O2 6 h 8 h Eye See neutralising solution*
BlueVision Ciba Vision 3.0% H2O2 6 h 8 h Eye See neutralising solution*
Easy Sept Bausch & Lomb 3.0% H2O2 6 h 8 h Eye See neutralising solution*
Oxysept Comfort AMO 3.0% H2O2 6 h 8 h Eye See neutralising solution*
Optifree Replenish Alcon 0.001% polyquad (polyquaternium-1), 0.0005% aldox
(myristamidopropyl dimethylamine)
6 h 8 h IA II**
Solocare Aqua Ciba Vision 0.0001% polyhexanide 4 h 8 h IA II**
MMRDT - manufacturer’s minimum recommended disinfection time.
* Eye See neutralising solution, Lapis Lazuli Int. NV: catalase, 0.01% EDTA, 0.002% merthiolate, isotonic buffer solution.
** inactivation solution II: 3% TSB (Roth, Karlsruhe, Germany), 3% polysorbate 80 (Serva, Heidelberg, Germany), 3% saponin (Fluka, Buchs, Switzerland),
0.1% L-histidine (Serva, Heidelberg, Germany), 0.1% L-cysteine (Merck, Darmstadt, Germany) in 1 L deionised water.
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solution and incubated at 25°C for the manufacturer’s
minimum recommended disinfection time (MMRDT) as
well as overnight (8 h) (Table 1). In a parallel series, all
experiments were performed likewise with the addition
of 0.1 ml artificial tear fluid as the organic load.
After disinfection, the active ingredients were neutra-
lised for 30 minutes at room temperature by transferring
1 ml of the incubated CL care solution into 9 ml of in-
activation solution, which was individually assessed for
each tested product (see Table 1). Afterwards, the serial
dilutions were placed on the appropriate agar according
to EN ISO 14729 [47]. Colonies were counted after 24 h
(for bacteria and C. albicans) of incubation at 37°C and
after 14 d (for F. solani) of incubation at 25°C. Colony
counting allowed calculation of the original viable bac-
terial cell concentration in log [CFU/ml]); the results
were reported as reduction factors of the log transform-
ation data (RF log [CFU/ml]) by subtracting the CL care
solution data from the control data. All experiments
were performed for at least three different batches.
According to EN ISO 14729 [47], the mean value of the
reduction factors of these three batches was calculated.
If the reduction factor of a batch was not an absolute
value, e.g., ≥ 5.0 log [CFU/ml], this data was assumed to
be the absolute value for the calculation, i.e., 5.0 log
[CFU/ml]. If the results differed by more than 0.5 log
[CFU/ml] from the mean value, the experiments
were repeated. All in controls demanded by the norm
were fulfilled.
Statistical analyses
Mean values and standard deviations of reduction fac-
tors are reported as descriptive statistics. For each CL
care solution and for each tested microorganism, the
proportion of reduction factors exceeding pre-specified
thresholds were calculated. The thresholds were deter-
mined according to the criteria specified in the EN ISO
14729 Stand Alone Test recommendations [47]: ≥ 3.0
log [CFU/ml] for bacteria and ≥ 1.0 log [CFU/ml] for
fungi. The thresholds ≥ 5.0 log [CFU/ml] for bacteria
according to the criteria in the norms EN 1040 [58], EN
13727 [59] and EN 1276 [60] and ≥ 4.0 log [CFU/ml] for
fungi according to the criteria in the norms EN 1275
[61], EN 13624 [62] and EN 1650 [63] were additionally
assessed for comparative purposes. The criteria of the
different norms were considered as met if the thresholds
were attained to at least 50%. Differences between pro-
portions of reduction factors for CL care solutions were
tested using the chi-square (χ2) test. In addition to ana-
lyses of the complete data set (1), subgroup analyses of
tests with vs. without organic load (2) and MMRDT vs.
overnight (3) were performed. P-values ≤ 0.05 were con-
sidered statistically significant.
Results
The disinfection efficacies of the six different CL care
solutions (Table 1) are reported in Table 2 without and
in Table 3 with artificial tear fluid as the organic load,
and additionally in Figure 1 without and in Figure 2 with
organic load. All these data are the mean values of RF
with standard deviation. Further, the calculated propor-
tions of RFs exceeding the pre-specified thresholds are
reported in Table 4 for each CL care solution and each
microorganism. Table 5 shows these proportions without
organic load and Table 6 with organic load. Reduction
factor results by the different disinfecting times
MMRDT and overnight are shown in Tables 7 and 8,
respectively.
The primary criteria of the Stand Alone Test recom-
mended in EN ISO 14729 [47] require a RF of ≥ 3 log
units for bacteria and ≥ 1 log unit for fungi. The results
show that only Aosept Plus met these criteria and even
exceeded them with > 6 log units for bacteria and > 4
log units for fungi without organic load (Tables 2 and 5).
With organic load, the product yields lower yet sufficient
RFs of > 5 for S. aureus and S. marcescens, and un-
changed high RFs for all other microorganisms. The har-
monised requirements for determining the efficacies of
chemical disinfectants and antiseptics, i.e., a RF of ≥ 5
log units for bacteria and ≥ 4 log units for fungi, are
solely met by Aosept Plus regardless of the test condi-
tions (Tables 4, 5, 6, 7, 8).
Although Blue vision, Easy Sept and Oxysept Comfort
also contain 3% hydrogen peroxide, these three products
yielded different results. BlueVision does not pass the
Stand Alone criteria due to insufficient efficacy against
S. aureus. The efficacy against the other microorganisms
is particularly high, with a RF > 7 log units for bacteria
and > 4 log unit for fungi. In the presence of organic
load, the efficacy of BlueVison against S. aureus
increases dramatically, while that against all other micro-
oraganisms is not affected by the organic load in any
way. The great increase of efficacy against S. aureus
enables the product to pass the Stand Alone criteria in
the presence of organic load. The criteria of the harmo-
nised norms for chemical disinfectants and antiseptics,
however, are still not met.
Without organic load, Easy Sept and Oxysept Comfort
exhibited behaviour similar to BlueVision, showing a lack
of efficacy against S. aureus and therefore not passing the
Stand Alone Test either. The positive effect of organic load
on the efficacy of BlueVision against S. aureus can only be
be slightly observed for Easy Sept. The efficacy of Oxysept
Comfort decreases even further. This means that Easy Sept
and Oxysept Comfort do not fulfill the requirements of
the Stand Alone Test, either with or without organic load.
Consequently, the criteria of the harmonised norms for
chemical disinfectants and antiseptics also cannot be met.
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Although the RFs for the polyquad-based CL care
product Optifree Replenish are generally lower than
those of the hydrogen-peroxide-based products, the
requirements of > 3 log units for bacteria and > 1 log
unit for fungi are met in the presence of organic load.
This again shows how the organic load can have a posi-
tive influence on the efficacy of the product. Without or-
ganic load, the product exhibits mostly lower RFs for
bacteria than with organic load and in the case of S. aur-
eus fails to meet the test criteria.
Solocare Aqua, the polyhexanide-based product, exhi-
bits the lowest RFs in all cases. The product passes the
Stand Alone Test neither with nor without organic load.
Nevertheless, the influence of organic load, can be
observed for Solocare Aqua as well: especially the effi-
cacy against P. aeruginosa increases greatly by more
than 2 log units. On C. albicans, the organic load has a
noticeable negative influence, reducing the efficacy by
nearly 2 log units.
Neither of the multi-purpose solutions (MPSs), Optifree
Replenish and Solocare Aqua, meet the criteria of the har-
monised norms for chemical disinfectants and antiseptics.
The prolonged disinfection time (overnight) did not
noticeably influence the disinfection efficacy compared
to the MMRDT for any of the tested CL care solutions.
The χ2 test shows that in most cases, the disinfection
efficacies significantly differ between the different CL
care solutions.
Discussion
Many studies in the past have determined the disinfect-
ing efficacy of polyhexanide- or polyquad-based multi-
purpose solutions (MPSs) and hydrogen-peroxide-based
CL care solutions according to the primary criteria of
Table 2 Mean values of reduction factors of six different contact lens care solutions in log [CFU/ml] without organic
load. Standard deviations are given in parentheses
CL care solution Time S. aureus P. aeruginosa S. marcescens C. albicans F. solani
Aosept Plus 6 h > 6.7 (0.23) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
8 h > 6.7 (0.23) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
BlueVision 6 h 1.3 (0.15) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
8 h 1.2 (0.12) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
Easy Sept 6 h 1.5 (0.35) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
8 h 1.3 (0.15) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
Oxysept Comfort 6 h 2.3 (0.17) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
8 h 2.3 (0.29) > 7.0 (0.21) > 7.0 (0.10) > 4.2 (0.20) > 5.0 (0.06)
Optifree Replenish 6 h 2.4 (0.35) 5.2 (2.16) 3.5 (0.66) 2.1 (1.18) 4.4 (1.20)
8 h 2.5 (0.25) > 7.1 (0.17) 4.5 (1.21) 2.8 (1.22) > 4.9 (0.20)
Solocare Aqua 4 h 0.3 (0.06) 1.6 (0.15) 0.5 (0.29) 2.6 (1.82) 3.5 (1.44)
8 h 0.4 (0.21) 1.5 (0.21) 0.6 (0.29) 2.9 (1.65) 4.0 (1.35)
Table 3 Mean values of reduction factors of six different contact lens care solutions in log [CFU/ml] with organic load.
Standard deviations are given in parentheses
CL care solution Time S. aureus P. aeruginosa S. marcescens C. albicans F. solani
Aosept Plus 6 h 5.5 (2.01) > 7.1 (0.12) 5.2 (2.05) > 5.3 (0.06) > 5.0 (0.06)
8 h 5.7 (1.81) > 7.1 (0.12) 5.2 (2.11) > 5.3 (0.06) > 5.0 (0.06)
BlueVision 6 h 5.0 (1.39) > 7.1 (0.12) > 7.0 (0.15) > 5.3 (0.06) > 5.0 (0.06)
8 h 4.8 (1.64) > 7.1 (0.12) > 7.0 (0.15) > 5.3 (0.06) > 5.0 (0.06)
Easy Sept 6 h 2.5 (1.05) > 7.1 (0.12) > 7.0 (0.15) > 5.3 (0.06) > 5.0 (0.06)
8 h 2.3 (0.82) > 7.1 (0.12) > 7.0 (0.15) > 5.3 (0.06) > 5.0 (0.06)
Oxysept Comfort 6 h 1.7 (0.17) > 7.1 (0.12) > 7.0 (0.15) > 5.3 (0.06) > 5.0 (0.06)
8 h 1.6 (0.25) > 7.1 (0.12) > 7.0 (0.15) > 5.3 (0.06) > 5.0 (0.06)
Optifree Replenish 6 h 3.4 (0.55) > 7.1 (0.10) 5.0 (1.55) 1.1 (0.35) 4.2 (1.76)
8 h 3.5 (0.34) > 7.1 (0.10) 5.3 (1.28) 1.3 (0.36) 4.5 (1.08)
Solocare Aqua 4 h 0.9 (0.40) 3.5 (2.24) 0.9 (0.20) 0.8 (0.25) 3.7 (1.24)
8 h 1.1 (0.34) 4.1 (2.03) 1.2 (0.32) 1.0 (0.30) 4.2 (1.06)
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the Stand Alone Test of the EN ISO 14729 [41,45,50-
53,64-73]. Kramer et al. [45] and other authors [53,65,73]
investigated the disinfecting efficacy of various CL care
solutions including MPSs and hydrogen-peroxide-based
CL care solutions, and reported that the hydrogen-
peroxide-based CL care solution Aosept Plus proved to
be the most effective product, yielding reduction factors
of > 5 log units. This study also confirms that Aosept
Plus, a 3% hydrogen-peroxide-based CL care solution,
yields the best results independent of all influencing
factors, meets the primary criteria of the Stand Alone
Test, and furthermore fulfills the harmonised require-
ments for determining the efficacies of chemical disin-
fectants and antiseptics. For more than 20 years now, it
is known that CL care solutions based on 3% hydrogen
peroxide are mostly effective against a broad range of
microorganisms [74,75] also in practical settings
[76,77], but it is also known that their efficacies can
vary [45,53]. This study found differences in the effica-
cies against S. aureus, although the four tested hydro-
gen peroxide solutions have identical concentrations of
active ingredient. The same effect has been observed
for MPSs which are based on the same amount of ac-
tive ingredient, for example 0.0001% polyhexanide
[45,53,73]. Therefore, further ingredients such as salts,
buffers, surfactants, sequestering agents, or wetting
agents as well as the physical and chemical characteris-
tics of the tested CL care solutions must be major in-
fluencing factors and must have the ability to increase
the disinfection efficacies of CL care solutions
[12,69,78-81]. Thus, the active ingredient itself is not a
guarantee for sufficient disinfecting performance, and
proof of efficacy by meeting a harmonised norm is
essential.
Figure 1 Reduction factors of six different contact lens care solutions tested according to the Stand Alone Test
(quantitative suspension test) of the EN ISO 14729 without organic load. (Bars show the reduction factor of each contact lens care solution
for each microorganism: Staphylococcus aureus (horizontally-striped bars), Pseudomonas aeruginosa (fasciated bars), Serratia marcescens (hatched
bars), Candida albicans (dotted black bars) and Fusarium solani (dotted grey bars). Results are the mean values of the reduction factors in log
[CFU/ml] ± standard deviation (error bars) of at least three different batches. Min = MMRDT (manufacturer’s minimum recommended disinfection
time), Max = overnight (8h)).
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Figure 2 Reduction factors of six different contact lens care solutions tested according to the Stand Alone Test
(quantitative suspension test) of the EN ISO 14729 with organic load. (Bars show the reduction factor of each contact lens care solution for
each microorganism: Staphylococcus aureus (horizontally-striped bars), Pseudomonas aeruginosa (fasciated bars), Serratia marcescens (hatched bars),
Candida albicans (dotted black bars) and Fusarium solani (dotted grey bars). (Results are the mean values of the reduction factors in
log [CFU/ml] ± standard deviation of at least three different batches. Min = MMRDT (manufacturer’s minimum recommended disinfection
time), Max = overnight (8h)).
Table 4 Proportions of reduction factors exceeding pre-specified thresholds for each CL care solution and for each
tested microorganism / complete data set
S. aureus P. aeruginosa S. marcescens C. albicans F. solani
RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 1 RF ≥ 4 RF ≥ 1 RF ≥ 4
% N % N % N % N % N % N % N % N % N % N
AOSEPT PLUS 88.9 18 77.8 18 100 12 100 12 88.9 18 66.7 18 100 12 100 12 100 12 100 12
BlueVision 61.1 18 22.2 18 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12
Easy Sept 11.1 18 0 18 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12
Oxysept Comfort 0 12 0 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12
Optifree Replenish 61.1 18 0 18 94.4 18 83.3 18 95.8 24 20.8 24 94.4 18 16.7 18 95.8 24 87.5 24
Solocare Aqua 0 18 0 18 38.9 18 11.1 18 0 12 0 12 77.8 18 22.2 18 100 24 58.3 24
χ2 test < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.041 < 0.001 0.695 < 0.001
The intervals ≥ 3.0 log [CFU/ml] for bacteria and ≥ 1.0 log [CFU/ml] for fungi were assessed according to the criteria of the EN ISO 14729 Stand Alone Test [47].
The intervals ≥ 5.0 log [CFU/ml] for bacteria according to the criteria of the norms EN 1040 [58], EN 13727 [59] and EN 1276 [60] and ≥ 4.0 log [CFU/ml] for fungi
according to the criteria of the norms EN 1275 [61], EN 13624 [62] and EN 1650 [63] were assessed.
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Comparing MPSs, it has often been reported that
polyquad-based CL care solutions such as Optifree are
more effective than polyhexanide-based CL care solu-
tions [41,53,70,72], which is in line with the findings of
this study. In particular Solocare Aqua seems to possess
hardly any antimicrobial and antifungal characteristics
[53]. These findings are in agreement with those of a re-
cent in-vivo study by Nzeako et al. [12], who examined
the microbial contamination of various commonly used
CL care solutions. MPSs, especially those based on poly-
hexanide or related active ingredients, were found to be
contaminated with Gram-negative bacteria, in particular
P. aeruginosa, yeasts (Candida spp.), moulds, and Gram-
positive bacteria (especially S. marcescens) as well. The
high number of contaminated MPSs reported in in-vivo
studies [12,25,45,46] and the association of MPSs
with an increased risk of CL-related microbial keratitis
[38-44] suggest that MPSs – especially those based on
polyhexanide or related active ingredients –should be
improved to yield higher antimicrobial and antifungal
characteristics, and therefore should be tested under
more realistic conditions before being placed on the
market.
Especially the influence of the tear fluid and its com-
ponents is an important factor for simulating more real-
istic conditions. Thus, different studies have reappraised
the effect of organic load on test results [45,53,72,82],
for example, 0.2% bovine albumin [45], 0.2% mucine
[73] or even more contaminated conditions with 1% al-
bumin and 0.1% mucine [53]. All these studies exhibit
similar results; organic load has a negative effect on the
disinfecting efficacy of a number of CL care solutions.
Still another organic load was used in this study: a spe-
cial artificial tear fluid consisting of human blood serum,
lysozyme and mucine to mimic realistic test settings. Al-
though human blood serum represents a useful analogue
to human tear fluid, serum has a higher protein concen-
tration, lower quantities of antimicrobial substances, and
lacks tear-specific proteins. Therefore, the tear-specific
proteins lysozyme and mucine were added. This study
revealed that in the presence of the described artificial
tear fluid, the disinfecting efficacy against S. aureus
Table 5 Proportions of reduction factors exceeding pre-specified thresholds for each CL care solution and for each
tested microorganism / without organic load
S. aureus P. aeruginosa S. marcescens C. albicans F. solani
RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 1 RF ≥ 4 RF ≥ 1 RF ≥ 4
% N % N % N % N % N % N % N % N % N % N
AOSEPT PLUS 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
BlueVision 0 6 0 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Easy Sept 0 6 0 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Oxysept Comfort 0 6 0 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Optifree Replenish 0 6 0 6 91.7 12 75 12 91.7 12 8.3 12 100 12 25 12 100 12 91.7 12
Solocare Aqua 0 6 0 6 0 6 0 6 0 6 0 6 91.7 12 33.3 12 100 12 58.3 12
χ2 test < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.690 < 0.001 1 0.024
The intervals ≥ 3.0 log [CFU/ml] for bacteria and ≥ 1.0 log [CFU/ml] for fungi were assessed according to the criteria of the EN ISO 14729 Stand Alone Test [47].
The intervals ≥ 5.0 log [CFU/ml] for bacteria according to the criteria of the norms EN 1040 [58], EN 13727 [59] and EN 1276 [60] and ≥ 4.0 log [CFU/ml] for fungi
according to the criteria of the norms EN 1275 [61], EN 13624 [62] and EN 1650 [63] were assessed.
Table 6 Proportions of reduction factors exceeding pre-specified thresholds for each CL care solution and for each
tested microorganism / with organic load
S. aureus P. aeruginosa S. marcescens C. albicans F. solani
RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 1 RF ≥ 4 RF ≥ 1 RF ≥ 4
% N % N % N % N % N % N % N % N % N % N
AOSEPT PLUS 83.3 12 66.7 12 100 6 100 6 83.3 12 50 12 100 6 100 6 100 6 100 6
BlueVision 91.7 12 33.3 12 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Easy Sept 16.7 12 0 12 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Oxysept Comfort 0 6 0 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Optifree Replenish 91.7 12 0 12 100 6 100 6 100 12 33.3 12 83.3 6 0 6 91.7 12 83.3 12
Solocare Aqua 0 12 0 12 58.3 12 16.7 12 0 6 0 6 50 6 0 6 100 12 58.3 12
χ2 test < 0.001 < 0.001 0.014 <0.001 < 0.001 < 0.001 0.03 < 0.001 0.69 0.047
The intervals ≥ 3.0 log [CFU/ml] for bacteria and ≥ 1.0 log [CFU/ml] for fungi were assessed according to the criteria of the EN ISO 14729 Stand Alone Test [47].
The intervals ≥ 5.0 log [CFU/ml] for bacteria according to the criteria of the norms EN 1040 [58], EN 13727 [59] and EN 1276 [60] and ≥ 4.0 log [CFU/ml] for fungi
according to the criteria of the norms EN 1275 [61], EN 13624 [62] and EN 1650 [63] were assessed.
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surprisingly increases for most CL care solutions, and in
particular for BlueVision and Optifree Replenish, which
then pass the primary criteria of the Stand Alone Test.
This increased efficacy has also been observed for Solo-
care Aqua against P. aeruginosa, whereas the presence of
organic load seems to have no effect on the efficacies
against S. marcescens and F. solani. In contrast, the yeast
C. albicans was more resistant to the MPSs in the pres-
ence of the artificial tear fluid. This unequal effect on the
disinfecting efficacies of the different CL care solutions
can possibly be explained by the antimicrobial character-
istics of lysozyme and other proteins in the artificial tear
fluid. Lysozyme, also called N-acetylmuramidase, is an
enzyme with antimicrobial activity against a wide range
of microorganisms [83-88]. This enzyme catalyses the hy-
drolysis of 1.4-β-bonds between N-acetylmuramic acid
(NAM) and N-acetylglucosamine (NAG) residues in the
peptidoglycan polymers of bacterial cells, also called
murein, resulting in the lysis of the sensitive bacterial
cells [83]. Mostly Gram-positive bacteria, such as S. aur-
eus, are susceptible to lysozyme due to their freely
accessible murein cell wall [83]. It has been reported that
the antibacterial effect of lysozyme can vary between dif-
ferent bacterial species and strains and that it can be
influenced by additional substances (lactoferrin, EDTA
etc.) or changes in environmental conditions (pH value,
temperature, pressure, etc.) [83-88]. These influences
may explain the findings in this study: the noticeably
increased efficacy against the Gram-positive bacterium S.
aureus, the slightly increased or lack of efficacy against
the Gram-negative bacteria P. aeruginosa and S. marces-
cens, respectively. Through the observation that the arti-
ficial tear fluid used in this study influences the
disinfecting efficacy of CL care solutions, especially that
of MPSs, in a different way than do albumin, mucine or
even the organic load suggested in EN ISO 14729, it
becomes obvious that the test conditions in the EN ISO
14729 should be revised to create more realistic condi-
tions, e.g., by using a more realistic artificial tear fluid.
Since the EN ISO 14729 was adopted in 2001, Kramer
et al. [45] have criticised the following points: i. efficacy
testing with organic load is only mentioned as an option
Table 7 Proportions of reduction factors exceeding pre-specified thresholds for each CL care solution and for each
tested microorganism after MMRDT
S. aureus P. aeruginosa S. marcescens C. albicans F. solani
RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 1 RF ≥ 4 RF ≥ 1 RF ≥ 4
% N % N % N % N % N % N % N % N % N % N
AOSEPT PLUS 88.9 9 77.8 9 100 6 100 6 88.9 9 66.7 9 100 6 100 6 100 6 100 6
BlueVision 66.7 9 22.2 9 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Easy Sept 11.1 9 0 9 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Oxysept Comfort 0 6 0 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Optifree Replenish 55.6 9 0 9 88.9 9 66.7 9 91.7 12 16.7 12 88.9 9 11.1 9 91.7 12 83.3 12
Solocare Aqua 0 9 0 9 33.3 9 11.1 9 0 6 0 6 66.7 9 22.2 9 100 12 50 12
χ2 test < 0.001 < 0.001 0.001 < 0.001 < 0.001 < 0.001 0.132 < 0.001 0.69 0.013
The intervals ≥ 3.0 log [CFU/ml] for bacteria and ≥ 1.0 log [CFU/ml] for fungi were assessed according to the criteria of the EN ISO 14729 Stand Alone Test [47].
The intervals ≥ 5.0 log [CFU/ml] for bacteria according to the criteria of the norms EN 1040 [58], EN 13727 [59] and EN 1276 [60] and ≥ 4.0 log [CFU/ml] for fungi
according to the criteria of the norms EN 1275 [61], EN 13624 [62] and EN 1650 [63] were assessed.
Table 8 Proportions of reduction factors exceeding pre-specified thresholds for each CL care solution and for each
tested microorganism after overnight disinfection
S. aureus P. aeruginosa S. marcescens C. albicans F. solani
RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 3 RF ≥ 5 RF ≥ 1 RF ≥ 4 RF ≥ 1 RF ≥ 4
% N % N % N % N % N % N % N % N % N % N
AOSEPT PLUS 88.9 9 77.8 9 100 6 100 6 88.9 9 66.7 9 100 6 100 6 100 6 100 6
BlueVision 55.6 9 22.2 9 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Easy Sept 11.1 9 0 9 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Oxysept Comfort 0 6 0 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6 100 6
Optifree Replenish 66.7 9 0 9 100 9 100 9 100 12 25 12 100 9 22.2 9 100 12 91.7 12
Solocare Aqua 0 9 0 9 44.4 9 11.1 9 0 6 0 6 88.9 9 22.2 9 100 12 66.7 12
χ2 test < 0.001 < 0.001 0.001 <0.001 < 0.001 < 0.001 0.585 < 0.001 1 0.087
The intervals ≥ 3.0 log [CFU/ml] for bacteria and ≥ 1.0 log [CFU/ml] for fungi were assessed according to the criteria of the EN ISO 14729 Stand Alone Test [47].
The intervals ≥ 5.0 log [CFU/ml] for bacteria according to the criteria of the norms EN 1040 [58], EN 13727 [59] and EN 1276 [60] and ≥ 4.0 log [CFU/ml] for fungi
according to the criteria of the norms EN 1275 [61], EN 13624 [62] and EN 1650 63] were assessed.
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and the type of organic load is not specified; ii. for bac-
teria, the test protocol neither includes data on the
standard deviation nor on the number of test reproduc-
tions necessary for statistical significance; iii. a RF of 1
log unit for C. albicans and F. solani cannot be exactly
ascertained experimentally and falls within the scatter
range of the quantitative suspension test (± 0.5 log); iv.
neutralisation testing is not adequately defined and must
be described more precisely; v. testing against Acanth-
amoeba species is not recommended but should be
defined with a RF of at least > 2 log units; vi. compared
to other harmonised norms, the required RFs are too for
evaluating the microbicidal efficacy of disinfectants; vii. a
test under practical conditions (Regimen Test) is only
required if the primary criteria of the Stand Alone Test
are not met. Further critical points must be considered
when testing CL care solution: i. laboratory strains may
be inadequate for assuring that the CL care solutions
will be equally effective against clinical isolates
[41,66,68,89-91].; ii. After extended periods of storage,
the disinfecting efficacy of polyhexanide-based MPSs
may decrease due to the accumulation of polyhexanide
on the CL material or CL case [70,92]; iii. higher storage
temperatures can lead to decreased disinfecting efficacies
[93]; longer storage times of open hydrogen-peroxide-
based CL care solutions can lead to a decrease of the
hydrogen peroxide concentration and thus decreased
disinfecting efficacy.
Bearing a number of these influences in mind, some
changes were incorporated into the EN ISO 14729 [94]
in 2010: i. clarification of the criteria of the Stand Alone
Test for moulds (CL care solution direct test); ii. changes
in the recommendations regarding the rub-and-/or-rinse
steps to the effect that if the CL care solution can be used
without a rub and-/or-rinse step according to the manu-
facturer’s instructions, the CL care solution must pass
the secondary criteria of the Stand Alone Test as well as
the criteria of the Regimen Test in the presence of or-
ganic load; iii. incorporation of requirements for testing
CL care solutions for use on silicone hydrogel CLs. Des-
pite these changes, the aspects which have been criticised
in the past still have not been adequately addressed in
this amendment. Especially the demands for i. stricter re-
duction factors, ii. a quantitative suspension with and
without organic load in combination with a test simulat-
ing practical conditions, and iii. a specified and realistic
artificial tear fluid as organic load have been neglected.
In the European test hierarchy for chemical disinfec-
tants and antiseptics, stricter reduction factors of ≥ 5 log
units for bacteria and ≥ 4 log units for fungi are recom-
mended in each test norm regardless of the type of test
(quantitative suspension test or practical setting). These
harmonised requirements could also be adequate criteria
for the determination of the efficacies of CL care
solutions. Furthermore, the European test hierarchy is a
system of three tests: phase 1 (quantitative suspension
test without organic load); phase 2 step 1 (quantitative
suspension test with organic load); phase 2 step 2 (car-
rier test - practical settings). All three tests must be per-
formed and passed in order to determine the
bactericidal and fungicidal efficacies of chemical disin-
fectants and antiseptics. This system is another improve-
ment that could be made in the testing of CL care
solutions. Moreover, improvements to the Regimen Test
as a phase 2 steps 2 test have recently been suggested in
order to provide a more realistic evaluation of applicable
CL care disinfecting solutions [95].
Conclusions
Because artificial tear fluid influences the disinfecting ef-
ficacy of contact lens care solutions, especially that of
multi-purpose solutions, in a different way than does al-
bumin, mucine, or the organic load suggested in EN ISO
14729, it becomes obvious that the test conditions in the
EN ISO 14729 should be revised in order to create more
realistic conditions, e.g., by using a more realistic artifi-
cial tear fluid. Furthermore, we suggest adapting the EN
ISO 14729 to the European test hierarchy for chemical
disinfectants and antiseptics, which consists of three test
phases and also requests meeting stricter criteria in
order to pass the test.
The CL industry itself has also started to respond to
the criticism by enhancing their CL care products, e.g.,
AMO Eyecare with its product COMPLETEW Revita-
Lens, Alcon’s Opti-Free EverMoist or Bausch & Lomb’s
BiotrueTM. These three products have an increased con-
centration of active ingredients, combinations of active
ingredients have been introduced (polyquad together
with another active ingredient such as a biguanide or an
amidoamine), and the recommendation to perform an
adequate rub-and-rinse step has been revived. However,
it is not expected that the compliance rate of CL wearers
with their CL care regimen will increase considerably,
and, therefore, the criteria to evaluate the disinfecting ef-
ficacy of CL care products must be made substantially
more rigorous and a certain safety margin should be
included. Critical CL care products would then dis-
appear from the market leaving those products that ex-
hibit an adequate disinfecting efficacy. This way it is
possible to counteract the careless behaviour of the great
majority of CL wearers and the risk of CL-related micro-
bial keratitis and other infections will be decreased.
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